Canaccord Genuity analyst John Newman downgraded bluebird bio (NASDAQ: BLUE) from Buy to Hold with a price target of $20.00.

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $18.16 yesterday.